Update on emerging infections: news from the Centers for Disease Control and Prevention.
Moran
Gregory J
GJ
Department of Emergency Medicine, Olive View-UCLA Medical Center, Sylmar, CA, USA.
Mount
Jason
J
D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002487:Centers for Disease Control and Prevention, U.S.; D017714:Community-Acquired Infections / Q000188:drug therapy; D000075202:Contraindications; D024881:Drug Resistance, Bacterial / Q000235:genetics; D004636:Emergency Service, Hospital; D006801:Humans; D017053:Infection Control; D008712:Methicillin / Q000494:pharmacology; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D010068:Oxacillin / Q000494:pharmacology; D010403:Penicillin Resistance; D010406:Penicillins / Q000494:pharmacology; D017410:Practice Guidelines as Topic; D006435:Renal Dialysis; D012307:Risk Factors; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000517:prevention & control / Q000635:transmission; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D014481:United States; D014486:United States Food and Drug Administration; D014640:Vancomycin / Q000494:pharmacology / Q000627:therapeutic use*; D020713:Vancomycin Resistance / Q000235:genetics; D018440:beta-Lactam Resistance
D000900:Anti-Bacterial Agents; D010406:Penicillins; D014640:Vancomycin; D008712:Methicillin; D010068:Oxacillin